Accueil   Diary - News   All news GeNeuro and the Karolinska Institutet/Academic Specialist Center of Stockholm agree to launch a new clinical study of temelimab in multiple sclerosis

GeNeuro and the Karolinska Institutet/Academic Specialist Center of Stockholm agree to launch a new clinical study of temelimab in multiple sclerosis

 

 

 

 

 

  • Collaboration follows data from ANGEL-MS extension to Phase 2 MS trial
  • Aims to address key unmet need of slowing or stopping disease progression

 


Geneva, Switzerland, November 25, 2019 – 7:30am CET – GeNeuro (Euronext Paris: CH0308403085 - GNRO), announced today a collaboration for a new clinical trial of temelimab in multiple sclerosis (MS) with clinical researchers of Karolinska Institutet and the Academic Specialist Center (ASC), Stockholm, Sweden. This single-center study will be led by Dr. Fredrik Piehl, Professor of Neurology at the Department of Clinical Neurosciences of the Karolinska Institutet, and head of research at the MS clinic at ASC.

 


The trial will be conducted at Center for Neurology of ASC, the largest MS center in Sweden with approximately 2,400 patients. The one-year trial will enroll patients whose disability progresses without relapses, and will document the safety and tolerability of temelimab following higher doses, as well as efficacy based on the latest biomarkers associated with disease progression. The study aims to start enrolling patients in Q1 2020.

 

 

Read the press release

By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to dpo@lyonbiopole.com. More details are available by clicking here I agree